Year archive

Innate Pharma — 2011 filings

All 38 regulatory filings released by Innate Pharma (IPH) in 2011, sourced directly from the official regulator.

38 Filings

2011 Period

2011 filings (38)

Filing	Released	Lang
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation au Salon Actionaria qui se tiendra au Palais des Congrès de Paris les 18 et 19 novembre 2011 Report Publication Announcement	2011-11-04	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris Regulatory Filings	2011-11-04	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce son chiffre d’affaires pour les neufs premiers mois de l'année 2011 et fait le point sur sa trésorerie Earnings Release 9M 2011	2011-11-04	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first nine months of 2011 and updates on its cash position Earnings Release 9M 2011	2011-11-04	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation à deux prochaines conférences investisseurs Report Publication Announcement	2011-09-14	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) to present at two upcoming investor conferences Report Publication Announcement	2011-09-14	English
Rapport financier semestriel 2011 de la société INNATE PHARMA Interim / Quarterly Report H1 2011	2011-09-06	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), la société de l’immunité innée, développant des médicaments innovants contre le cancer et les maladies inflammatoires, annonce aujourd’hui ses ré Interim / Quarterly Report H1 2011	2011-08-31	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its financial results for the f Interim / Quarterly Report H1 2011	2011-08-31	English
Bilan semestriel du contrat de liquidité INNATE PHARMA avec la société NATIXIS SECURITIES Report Publication Announcement	2011-07-18	French
Half-year report on Innate Pharma's liquidity contract with Natixis Securities Capital/Financing Update	2011-07-18	English
Bristol-Myers Squibb et Innate Pharma annoncent un accord de licence sans précédent sur un médicament d’origine biologique en développement dans le domaine de l’immuno-oncologie Regulatory Filings	2011-07-06	French
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic Regulatory Filings	2011-07-06	English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce les résultats de son Assemblée générale mixte qui s’est tenue à Marseille, le 29 juin 2011. AGM Information	2011-06-29	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France. AGM Information	2011-06-29	English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la tenue de son assemblée générale annuelle le 29 juin 2011 à Marseille. AGM Information	2011-05-26	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France. AGM Information	2011-05-26	English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce le renforcement de son équipe de direction avec la nomination de Catherine Moukheibir à son Directoire Board/Management Information	2011-05-05	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board Board/Management Information	2011-05-05	English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’affaires au 31 mars 2011 et fait le point sur sa trésorerie Earnings Release Q1 2011	2011-05-05	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first quarter of 2011 and updates on its cash position Earnings Release Q1 2011	2011-05-05	English
Innate Pharma et Transgene annoncent la création de Platine Pharma Services, nouvelle société de prestation de services d’immunomonitoring Regulatory Filings	2011-05-04	French
Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services Regulatory Filings	2011-05-04	English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la mise à disposition de son Document de Référence 2010 comprenant le Rapport Financier Annuel Report Publication Announcement	2011-05-03	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2010 Reference Document, including the Annual Financial Report Report Publication Announcement	2011-05-03	English
DOCUMENT DE REFERENCE ET RAPPORT FINANCIER ANNUEL, INNATE PHARMA SA Annual Report FY 2010	2011-05-02	French
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) fait le point sur ses prochains rendez-vous avec la communauté financière Report Publication Announcement	2011-03-23	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) updates on its next meetings with analysts and investors Report Publication Announcement	2011-03-23	English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce ses résultats pour 2010 et fait un point sur ses produits en développement Earnings Release FY 2010	2011-03-02	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports 2010 financial results and updates on its drug candidates Earnings Release FY 2010	2011-03-02	English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) receives a milestone payment for IPH 2201, a monoclonal antibody licensed to Novo Nordisk A/S Regulatory Filings	2011-02-28	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) reçoit un paiement d’étape pour IPH 2201, un anticorps monoclonal licencié à Novo Nordisk A/S Regulatory Filings	2011-02-28	French
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce des produits opérationnels de 4,3 millions d’euros pour 2010 Earnings Release FY 2010	2011-02-04	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 4.3 million euros for the year 2010 Earnings Release FY 2010	2011-02-04	English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce que le National Cancer Institute initie un essai clinique de Phase II avec l’anticorps d’Innate Pharma IPH 2101 Regulatory Filings	2011-01-12	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the US National Cancer Institute starts a Phase II clinical trial with Innate Pharma's IPH 2101 Regulatory Filings	2011-01-12	English
Bilan semestriel du contrat de liquidité INNATE PHARMA avec la société NATIXIS SECURITIES Regulatory Filings	2011-01-07	French
Half-year report on INNATE PHARMA's liquidity contract with NATIXIS SECURITIES Regulatory Filings	2011-01-07	English

Filings by year

2026 40 filings
2025 135 filings
2024 136 filings
2023 150 filings
2022 124 filings
2021 123 filings
2020 67 filings
2019 127 filings
2018 50 filings
2017 50 filings
2016 74 filings
2015 51 filings
2014 55 filings
2013 37 filings
2012 46 filings
2011 38 filings
2010 41 filings
2009 50 filings
2008 9 filings